Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 10/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11790270 | 0.82 | LMNA (0.64) | CYP19A1LMNAMAPTCYP3A4SMN1; SMN2 | |
| SCHEMBL17775770 | 0.82 | LMNA (0.77) | CYP19A1LMNAMAPTCYP3A4 | |
| Testolactone SCHEMBL2300061 | 0.80 | CYP19A1 (1.00) | CYP19A1LMNAMAPTCYP3A4 | |
| Testolactone SCHEMBL4053 | 0.80 | CYP19A1 (1.00) | CYP19A1LMNAMAPTCYP3A4 | |
| SCHEMBL10861103 | 0.80 | LMNA (0.81) | CYP19A1LMNAMAPTCYP3A4NR3C1 | |
| Methandrostenolone SCHEMBL8408550 | 0.80 | LMNA (1.00) | CYP19A1LMNAMAPTCYP3A4NR3C1 | |
| SCHEMBL5270893 | 0.80 | LMNA (0.81) | CYP19A1LMNAMAPTCYP3A4NR3C1 | |
| Methandrostenolone SCHEMBL4435272 | 0.80 | LMNA (1.00) | CYP19A1LMNAMAPTCYP3A4NR3C1 | |
| Methandrostenolone SCHEMBL21177905 | 0.80 | LMNA (1.00) | CYP19A1LMNAMAPTCYP3A4NR3C1 | |
| Methandrostenolone SCHEMBL16755284 | 0.80 | LMNA (1.00) | CYP19A1LMNAMAPTCYP3A4NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325918-A1 | Synthesis and separation of optically active isomers and cyclopropyl derivatives of spironolactone and their biological action | SOMBERG JOHN C | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325918-A1 | Synthesis and separation of optically active isomers and cyclopropyl derivatives of spironolactone and their biological action | HSD17B7, CYP17A1, HSD17B11 | CYP19A1 6/4885LMNA 1139/4885MAPT 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.